228 Results for "

CGMP

" in MedChemExpress (MCE) Product Catalog:
Products (228)

228 Results for "CGMP" in MCE Product Catalog:

Cat. No.: HY-P1556A
Target:  

PKG

Research Areas:  

Metabolic Disease

Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .
loading...
    loading...
Cat. No.: HY-P3624
CAS No.: 507289-11-4
Target:  

Guanylate Cyclase

Research Areas:  

Cardiovascular Disease

Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research .
loading...
    loading...
Cat. No.: HY-N7126R
CAS No.: 106-23-0
Citronellal (Standard) is the analytical standard of Citronellal. This product is intended for research and analytical applications.Citronellal is a monoterpene that can be found in the essential oils in various aromatic species of plants, with antiinflammatory and antinociceptive properties. Citronellal attenuates mechanical nociception, mediated in part by the NO-cGMP-ATP-sensitive K+ channel pathway. Citronellal induces reduction of spontaneuous activity, ataxia, analgesia, and sedation in vivo. Citronellal can attenuate mechanical nociception response in mouse model .
loading...
    loading...
Cat. No.: HY-P2281
CAS No.: 91917-63-4
Synonyms: Atrial natriuretic peptide (1-28)
Atrial natriuretic factor (1-28) (human, porcine) exhibits blood pressure lowering activity by increasing sodium and urine excretion. Atrial natriuretic factor (1-28) (human, porcine) inhibits the release of pituitary adrenocorticotropic hormone (ACTH) and beta-endorphin through inhibition of pro-opiomelanocortin (POMC) expression. Atrial natriuretic factor (1-28) (human, porcine) increases cGMP levels in RMIC cells with an IC50 of 1.2 nM .
loading...
    loading...
Cat. No.: HY-119708A
CAS No.: 3098314-20-3
Synonyms: RPL-554 tosylate
Research Areas:  

Inflammation/Immunology

Ensifentrine (RPL-554) tosylate is an inhaled dual inhibitor of PDE3 and PDE4 with IC50s of 0.4 nM and 1479 nM, respectively. Ensifentrine tosylate blocks PDE3 and PDE4 enzymes, thereby increasing the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in lung cells, dilating the bronchi, and inhibiting the activation and migration of inflammatory cells. Ensifentrine tosylate can be used in the research of chronic obstructive pulmonary disease (COPD) .
loading...
    loading...
Cat. No.: HY-174130
Target:  

Parasite PI4K PKG

Research Areas:  

Infection

PI4Kβ/PKG-IN-1 (Compound 19) is an orally active dual inhibitor targeting Plasmodium phosphatidylinositol 4-kinase beta (PI4Kβ) and cGMP-dependent protein kinase (PKG). PI4Kβ/PKG-IN-1 exhibits potent antiplasmodial activity. PI4Kβ/PKG-IN-1 is promising for research of malaria .
loading...
    loading...
Cat. No.: HY-174134
CAS No.: 3099010-20-2
Target:  

PI4K PKG Parasite

Research Areas:  

Infection

PI4Kβ/PKG-IN-2 (Compound 20) is an orally active dual inhibitor of Plasmodium phosphatidylinositol 4-kinase beta (PI4Kβ) and cGMP-dependent protein kinase (PKG). PI4Kβ/PKG-IN-2 has potent inhibitory effects on Plasmodium. PI4Kβ/PKG-IN-2 is promising for research of malaria .
loading...
    loading...
Cat. No.: HY-181755
CAS No.: 109621-29-6
Target:  

NO Synthase

Research Areas:  

Inflammation/Immunology

Phenylaminojuglone AJ-2 is a nitric oxide synthase inhibitor that interacts with soluble guanylate cyclase, β-adrenergic receptor, CaV1.2 calcium channel, KV channel and KCa channel. Phenylaminojuglone AJ-2 blocks extracellular Ca 2+ influx, regulates the activity of the NO?sGC?cGMP signaling pathway, and inhibits pharmacologic and electromechanical contractions of smooth muscle. Phenylaminojuglone AJ-2 is applicable to studies related to intestinal spasm .
loading...
    loading...
Cat. No.: HY-183283
CAII-IN-15 is a potent carbonic anhydrase II (CA II) inhibitor with a hCA II IC50 of 10 nM. CAII-IN-15 elevates cGMP levels, releases nitric oxide, reduces oxidative stress, and exhibits neuroprotective activity in vitro. CAII-IN-15 inhibits NLRP3 inflammasome activation, reduces neuronal apoptosis. CAII-IN-15 reduces Intraocular pressure (IOP) in rabbits. CAII-IN-15 can be used for the research of glaucoma .
loading...
    loading...
Cat. No.: HY-184303
Antihypertensive agent 7 is a vasodilator. Antihypertensive agent 7 acts on vascular endothelial cells to activate the PI3K/AKT signaling axis, increase phosphorylated eNOS, release NO, activate the sGC/cGMP pathway in smooth muscle cells, and synergistically activate multiple K + channels in vascular smooth muscle (Kir/Kv/KCa/KATP, thereby inducing endothelium-dependent vasodilation. Antihypertensive agent 7 can be used in the research of hypertension .
loading...
    loading...
Cat. No.: HY-B1639
CAS No.: 77671-31-9
Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC50 of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects .
loading...
    loading...
Cat. No.: HY-W013386R
CAS No.: 91300-60-6
LY83583 (Standard) is the analytical standard of LY83583 (HY-W013386). This product is intended for research and analytical applications. LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease .
loading...
    loading...
Cat. No.: HY-100984R
CAS No.: 84468-24-6
Research Areas:  

Cancer

HA-100 (Standard) is the analytical standard of HA-100 (HY-100984). This product is intended for research and analytical applications. HA-100 is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCK inhibitor .
loading...
    loading...
Cat. No.: HY-103160B
CAS No.: 51350-19-7
EHNA is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2)(IC50=4 μM) and adenosine deaminase (ADA). EHNA exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC50:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects .
loading...
    loading...
Cat. No.: HY-109039R
CAS No.: 1628730-49-3
Synonyms: IW-1973 (Standard)
Praliciguat (Standard) is the analytical standard of Praliciguat (HY-109039). This product is intended for research and analytical applications. Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase (sGC) activator. Praliciguat can increases cGMP via the nitric oxide (NO)-sGC pathway. Praliciguat can inhibit the expression of proinflammatory cytoKines and inhibit apoptosis. Praliciguat can promote vasodilation. Praliciguat can be used for the researches of metabolic disease and cardiovascular disease, such as hypertension, diabetes and heart failure .
loading...
    loading...
Cat. No.: HY-156434
CAS No.: 3027607-92-4
Research Areas:  

Neurological Disease

PDE11A4-IN-1 is a selective, cell-permeable inhibitor of phosphodiesterase 11A4 (PDE11A4) with an IC50 of 12 nM. PDE11A4-IN-1 inhibits PDE11A4-mediated hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) to the same extent. PDE11A4-IN-1 can be used in the research of age-related cognitive decline .
loading...
    loading...
Cat. No.: HY-173640
CAS No.: 2785317-21-5
Research Areas:  

Cancer

ID11916 is an orally active androgen receptor (AR) antagonist and a phosphodiesterase 5 (PDE5) inhibitor. ID11916 blocks androgen binding to AR, nuclear translocation, and androgen-dependent transcriptional activity of AR, while increasing intracellular cGMP levels and activating PKG via inhibition. ID11916 shows potent anti-cancer effect in prostate cancer cell lines VCaP and 22Rv1 and in AR-positive breast cancer cell lines SK-BR-3 .
loading...
    loading...
Cat. No.: HY-N7069
CAS No.: 536-60-7
Synonyms: Cuminic alcohol
4-Isopropylbenzyl alcohol (Cuminic alcohol) is an opioid-dependent analgesic. 4-Isopropylbenzyl alcohol activates opioid receptor, regulates the L-Arginine (HY-N0455)/NO/cGMP pathway, and reduces spinal cord TNF-α and IL-1β levels; it binds to BSA (HY-D0842) via static quenching. 4-Isopropylbenzyl alcohol can be used in research related to nociceptive pain, neuropathic pain, bacterial infection and diabetes .
loading...
    loading...
Cat. No.: HY-182426
CAS No.: 1202697-61-7
Target:  

Carbonic Anhydrase

Research Areas:  

Neurological Disease

NCX-278 is a human carbonic anhydrase inhibitor with a 13 nM Ki for hCA II, 410 nM Ki for hCA I, 181 nM Ki for hCA IV, and selective inhibition of hCA II over hCA IV. NCX-278 is a potent and effective stimulator of NO/sGC/cGMP signaling with an EC50 of 2.05 lM. NCX-278 exerts NO-mediated vascular relaxant effects. NCX-278 lowers intraocular pressure in normotensive rabbits. NCX-278 can be used for the research of open-angle glaucoma .
loading...
    loading...
Cat. No.: HY-189119
CAS No.: 646509-43-5
NMI-1182 is a nitric oxide-releasing prodrug of Naproxen (HY-15030). NMI-1182 is an orally active COX-1 and COX-2 inhibitor. NMI-1182 inhibits constitutive COX-1-mediated and inducible COX-2-mediated prostaglandin synthesis. NMI-1182 induces nitric oxide donor release, activating soluble guanylate cyclase to synthesize cGMP, causing vasodilation. NMI-1182 can be used for research on inflammation and pain .
loading...
    loading...